实用临床医药杂志2012，Vol.16Issue(21)：81-83,3.
恩度联合DP化疗方案治疗晚期非小细胞肺癌的临床研究
A feasibility study of endostar combined with platinum-based DP chemotherapy in the treatment of advanced non-small cell lung cancer
摘要
Abstract
Objective To evaluate the short-term therapeutic efficacy and safety of endostar combined with platinum-based DP (Docetaxel and Platinum) chemotherapy for patients with advanced non-small cell lung cancer (NSCLC). Methods Forty-five patients with histopathologically confirmed advanced NSCLC enrolled in this study received endostar plus DP regimen (endostar 7.5 mg/m2 day 1 to 14, repeated 21 days). All patients should complete 2 cycles at least. Results Of 45 patients enrolled in this study, the overall response rate and the clinical benefit rate was 40. 0% and 77.8% respectively, i.e. , 18 (40.0%) patients with PR, 17 (37.8%) with SD and 10(22. 2% ) with PD. The main side effects of myelosuppression toxicity and nausea/vomiting were usually tolerable after symptomatic treatment. Conclusion Administration of endostar combined with platinum-based DP chemotherapy for advanced NSCLC patients has a reliable short-term curative effect and low side effects, suggesting its potential worth for clinical application.关键词
非小细胞肺癌/恩度/联合化疗/DP方案Key words
non-small cell lung cancer/endostar/cisplatin/combined chemotherapy分类
医药卫生引用本文复制引用
郭维新,杨权烈..恩度联合DP化疗方案治疗晚期非小细胞肺癌的临床研究[J].实用临床医药杂志,2012,16(21):81-83,3.基金项目
中国高校医学期刊临床专项资金(11220205) （11220205）
